Argatroban Monohydrate is a direct thrombin inhibitor synthesised to bind to the catalytic site of the thrombin molecule. It binds rapidly and reversibly to both clot-bound and soluble thrombin. Argatroban produces a predictable dose response that is well correlated with changes in anticoagulant parameters[3]. Argatroban may have a complementary effect for preventing thrombus formation without aggravating bleeding tendency because of its monotarget specificity to thrombin. Intravenous administration (0.5 to 2 micrograms/kg/min) of argatroban is a safe anticoagulant for left heart bypass in repairs of traumatic aortic rupture associated with multiple organ injuries[4]. Argatroban, as compared with heparin, appears to enhance reperfusion with TPA (tissue plasminogen activator) in patients with AMI (acute myocardial infarction), particularly in those patients with delayed presentation[5]. Intravenous argatroban improved clinical outcomes and was generally well tolerated in adults with HIT (heparin-induced thrombocytopenia) or HIT with thrombosis syndrome (HITTS). Argatroban was safe and effective for improving short and long-term outcomes in noncardioembolic stroke patients[6].
Argatroban monohydrate 动物研究
Animal study
溶栓
动物：Wistar ST 大鼠，雄性，8周龄
给药: 2 mg/kg/h，静脉注射，持续1小时。
搜索
